search
Back to results

Dexmedetomidine vs Midazolam on Resting Energy Expenditure in Critically Ill Patients

Primary Purpose

Mechanical Ventilation, Dexmedetomidine, Midazolam

Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Dexmedetomidine
Midazolam
Fentanyl
Indirect calorimetry
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mechanical Ventilation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The study will be designed to recruit 30 critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for 2 days or longer.

Exclusion Criteria:

  • Age < 18 years old.
  • Pregnant patient.
  • Serious central nervous system pathologies (traumatic brain injury, acute stroke, uncontrolled seizures).
  • Patient who will require fraction of inspired oxygen more than 0.6.
  • Air leak from the chest tube.
  • Patient with body temperature > 39 Celsius.
  • Acute hepatitis or severe liver disease (Child-Pugh class C).
  • Left ventricular ejection fraction less than 30%.
  • Heart rate less than 50 beats/min.
  • Second or third degree heart block.
  • Systolic pressure < 90 mmHg despite of infusion of 2 vasopressors.
  • Patients with known endocrine dysfunction.
  • Patient with hypothermia
  • Patient on Positive end expiratory pressure more than 14 cmH2o

Sites / Locations

  • Cairo University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Dexmedetomidine group

midazolam group

Arm Description

Patients will receive analgesia with fentanyl at a fixed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug. Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1) Intervention: indirect calorimetry

Patients will receive analgesia with fentanyl at a fixed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug. Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1. Intervention: indirect calorimetry

Outcomes

Primary Outcome Measures

Change in Resting energy expenditure after drug administration
Resting energy expenditure will be measured using indirect calorimetry via metabolic module on General Electric ventilator

Secondary Outcome Measures

Heart rate
number of heart beats per minute
arterial blood pressure
arterial blood pressure measured in mmHg
Richmond agitation and sedation scale
range from -5 (unarousable) to +4 (combative)
Plasma interleukin-1β level
determined by ELISA using a quantitative sandwich enzyme immunoassay technique
Tumor necrosis factor-α plasma concentration
Enzyme immunoassay
partial pressure of oxygen in arterial blood
the partial pressure of oxygen in arterial blood measured in mmHg
VO2
the oxygen consumption measured in mL/Kg/min
VCO2
carbon dioxide production measured in mL/Kg/min
end-tidal co2
the pressure of carbon dioxide in expired air measured in mmHg
cardiac output
the amount of blood pumped by the heart during one minute

Full Information

First Posted
January 19, 2017
Last Updated
March 24, 2018
Sponsor
Cairo University
search

1. Study Identification

Unique Protocol Identification Number
NCT03030911
Brief Title
Dexmedetomidine vs Midazolam on Resting Energy Expenditure in Critically Ill Patients
Official Title
The Effect of Dexmedetomidine vs Midazolam on Resting Energy Expenditure in Critically Ill Patients: Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
January 1, 2017 (Actual)
Primary Completion Date
March 10, 2018 (Actual)
Study Completion Date
March 15, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to compare the effect of dexmedetomidine on resting energy expenditure in relation to the midazolam in critically ill patients using indirect calorimetry
Detailed Description
Caloric needs in critically-ill patients fluctuate significantly over the course of the disease which might expose patients to either malnutrition or overfeeding. Malnutrition is associated with deterioration of lean body mass, poor wound healing, increased risk of nosocomial infection, and weakened respiratory muscles. On the other hand overfeeding in medically compromised patients can promote lipogenesis, hyperglycemia, and exacerbation of respiratory failure. Many factors may affect the resting energy expenditure (REE) through manipulation of oxygen consumption (VO2). Sedatives are important contributors to reduction of REE. The postulated mechanism of sedative-induced reduction of VO2 is inhibition of circulating catecholamine and pro-inflammatory cytokines. Dexmedetomidine is a highly selective α2-adrenoceptor agonist. Stimulation of the α2-adrenoceptor in the central nervous system causes a 60-80% reduction in sympathetic outflow and endogenous catecholamine levels. It was found that perioperative use of α2 agonists decreased sympathetic activity with subsequent reduction of VO2 and REE. Moreover, dexmedetomidine, has some anti-inflammatory effect by inhibiting the pro-inflammatory cytokines which may cause additional reduction of REE in critically ill patient. Midazolam is another important sedative that is frequently used in critically-ill patient. Terao et al. found that increasing the depth of sedation using midazolam, decreased oxygen consumption and REE. However, it remains unclear whether the effect of midazolam on REE is related to the drug itself or to the depth of sedation. There is no direct comparison in the literature between dexmedetomidine and midazolam on REE.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mechanical Ventilation, Dexmedetomidine, Midazolam, Sedation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexmedetomidine group
Arm Type
Active Comparator
Arm Description
Patients will receive analgesia with fentanyl at a fixed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug. Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1) Intervention: indirect calorimetry
Arm Title
midazolam group
Arm Type
Placebo Comparator
Arm Description
Patients will receive analgesia with fentanyl at a fixed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug. Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1. Intervention: indirect calorimetry
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Other Intervention Name(s)
Precedex
Intervention Description
The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
Intervention Type
Drug
Intervention Name(s)
Midazolam
Other Intervention Name(s)
dormicum
Intervention Description
The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
Intervention Type
Drug
Intervention Name(s)
Fentanyl
Intervention Description
The drug will be administered in both groups
Intervention Type
Device
Intervention Name(s)
Indirect calorimetry
Other Intervention Name(s)
Calorimetry
Intervention Description
The device will be used for measurement of basal metabolic rate
Primary Outcome Measure Information:
Title
Change in Resting energy expenditure after drug administration
Description
Resting energy expenditure will be measured using indirect calorimetry via metabolic module on General Electric ventilator
Time Frame
The first baseline measurement will be taken before drug administration. The second measurement will be taken 24 hours after drug infusion.
Secondary Outcome Measure Information:
Title
Heart rate
Description
number of heart beats per minute
Time Frame
24 hours
Title
arterial blood pressure
Description
arterial blood pressure measured in mmHg
Time Frame
24 hours
Title
Richmond agitation and sedation scale
Description
range from -5 (unarousable) to +4 (combative)
Time Frame
24 hours
Title
Plasma interleukin-1β level
Description
determined by ELISA using a quantitative sandwich enzyme immunoassay technique
Time Frame
24 hours
Title
Tumor necrosis factor-α plasma concentration
Description
Enzyme immunoassay
Time Frame
24 hours
Title
partial pressure of oxygen in arterial blood
Description
the partial pressure of oxygen in arterial blood measured in mmHg
Time Frame
24 hours
Title
VO2
Description
the oxygen consumption measured in mL/Kg/min
Time Frame
24 hours
Title
VCO2
Description
carbon dioxide production measured in mL/Kg/min
Time Frame
24 hours
Title
end-tidal co2
Description
the pressure of carbon dioxide in expired air measured in mmHg
Time Frame
24 hours
Title
cardiac output
Description
the amount of blood pumped by the heart during one minute
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The study will be designed to recruit 30 critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for 2 days or longer. Exclusion Criteria: Age < 18 years old. Pregnant patient. Serious central nervous system pathologies (traumatic brain injury, acute stroke, uncontrolled seizures). Patient who will require fraction of inspired oxygen more than 0.6. Air leak from the chest tube. Patient with body temperature > 39 Celsius. Acute hepatitis or severe liver disease (Child-Pugh class C). Left ventricular ejection fraction less than 30%. Heart rate less than 50 beats/min. Second or third degree heart block. Systolic pressure < 90 mmHg despite of infusion of 2 vasopressors. Patients with known endocrine dysfunction. Patient with hypothermia Patient on Positive end expiratory pressure more than 14 cmH2o
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohamed Abdulatif, Professor
Organizational Affiliation
Professor and member of research committee of anesthesia department
Official's Role
Study Chair
Facility Information:
Facility Name
Cairo University
City
Cairo
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
19327188
Citation
Walker RN, Heuberger RA. Predictive equations for energy needs for the critically ill. Respir Care. 2009 Apr;54(4):509-21.
Results Reference
background
PubMed Identifier
14758147
Citation
Rubinson L, Diette GB, Song X, Brower RG, Krishnan JA. Low caloric intake is associated with nosocomial bloodstream infections in patients in the medical intensive care unit. Crit Care Med. 2004 Feb;32(2):350-7. doi: 10.1097/01.CCM.0000089641.06306.68.
Results Reference
background
PubMed Identifier
6794409
Citation
Covelli HD, Black JW, Olsen MS, Beekman JF. Respiratory failure precipitated by high carbohydrate loads. Ann Intern Med. 1981 Nov;95(5):579-81. doi: 10.7326/0003-4819-95-5-579.
Results Reference
background
PubMed Identifier
11288413
Citation
Fung EB. Estimating energy expenditure in critically ill adults and children. AACN Clin Issues. 2000 Nov;11(4):480-97. doi: 10.1097/00044067-200011000-00002.
Results Reference
background

Learn more about this trial

Dexmedetomidine vs Midazolam on Resting Energy Expenditure in Critically Ill Patients

We'll reach out to this number within 24 hrs